Literature DB >> 18980018

Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells.

Jun Zhao1, Motomu Kuroki, Hirotomo Shibaguchi, Lin Wang, Qun Huo, Noboru Takami, Toshihiro Tanaka, Tetsushi Kinugasa, Masahide Kuroki.   

Abstract

IgA is able to trigger antibody-dependent cellular cytotoxicity (ADCC) by recruiting neutrophils expressing the Fc receptor for the CHalpha chain. We herein describe the preparation of a human recombinant anti-CEA IgA antibody to kill carcinoembryonic antigen (CEA)-expressing tumor cells via ADCC by neutrophils. A single chain Fv (scFv) gene was constructed using a cDNA library of a hybridoma clone that produces a human anti-CEA monoclonal IgG4 (C2-45). The scFv gene, linked with a CHalpha gene, was inserted into the pBK283 vector, which was cotransfected into BmN4 insect cells with the wild-virus BmNPV. After cloning and amplification, the recombinated virus was injected into silkworm larvae. The resulting human recombinant IgA, designated as 45scFvLCHalpha, was purified from hemolymph by Ni-affinity chromatography and characterized by ELISA, Western blotting, and the ADCC assay. 45scFvLCHalpha with an IgA antigenicity was bound to CEA and showed effective killing of the CEA-expressing cells in the presence of IFN-gamma-activated neutrophils. These data suggest the recombinant anti-CEA IgA antibody recruiting neutrophils maybe a useful means for the antibody-based immunotherapy of human CEA-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980018     DOI: 10.3727/096504008786111374

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  4 in total

Review 1.  Immunoglobulin A: A next generation of therapeutic antibodies?

Authors:  Jantine E Bakema; Marjolein van Egmond
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

2.  Human IgA-binding peptides selected from random peptide libraries: affinity maturation and application in IgA purification.

Authors:  Takaaki Hatanaka; Shinji Ohzono; Mirae Park; Kotaro Sakamoto; Shogo Tsukamoto; Ryohei Sugita; Hiroyuki Ishitobi; Toshiyuki Mori; Osamu Ito; Koichi Sorajo; Kazuhisa Sugimura; Sihyun Ham; Yuji Ito
Journal:  J Biol Chem       Date:  2012-10-17       Impact factor: 5.157

Review 3.  Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy.

Authors:  Serena Zilio; Paolo Serafini
Journal:  Vaccines (Basel)       Date:  2016-09-09

4.  Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen.

Authors:  Hirotomo Shibaguchi; Naixiang Luo; Naoto Shirasu; Motomu Kuroki; Masahide Kuroki
Journal:  Onco Targets Ther       Date:  2017-08-22       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.